spacer
home > white papers > Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products - Entegris
WHITE PAPERS
logo_Entegris.jpg

Entegris

phone +1 978 436 6500
web http://https://www.entegris.com/en/home.html
email 129 Concord Road, Billerica, MA 01821

Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products

The pharmaceutical industry is migrating rapidly toward a world where drugs, vaccines, and specialized therapies are available on demand to patients anywhere around the globe. Whether accelerating clinical trials to bring new drugs to market or devel oping biosimilars to give more patients access to established commercial drugs, small and midsize production facilities stand to benefit from growing demand. To do so, however, they must be prepared to handle a broader mix of products and increase throughput without sacrificing safety or reliability, while at the same time keeping life-saving medica tions affordable. Such challenges become more difficult when working with products that must be stored and shipped in a frozen state.

Many pharmaceuticals — monoclonal antibodies, vaccines, and patient-specific therapeutics — must be reliably stored and transported at sub-zero temperatures, requiring a robust cold chain that contin ues throughout downstream processing (Figure 1). Demand for these pharmaceutical products is on the order of hundreds of kilograms per year and contin ues to increase.1 While large manufacturers are already well-equipped to handle these volumes, it is possible for smaller laboratories to quickly adapt to produce a wide variety of specialized drugs and distribute them without compromising safety or increasing financial risk.
Cold-chain Bioprocessing Readiness: Mitigating Risk and Protecting Pharmaceutical Products
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

BioIVT Acquires Cypex, a Leading Manufacturer of Drug-Metabolizing Enzymes

Westbury, NY – August 8, 2022 – BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced that it has acquired Cypex, a renowned manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland. Cypex’s extensive enzyme portfolio covers a wide range of proteins involved in drug metabolism.
More info >>


White Papers

Clinical Trial Disclosure Management: Build vs. Buy

TrialScope

Because software development is our core competency, TrialScope continues to make a significant investment in our technology. We employ agile methodologies to ensure that we can maintain a continuing level of responsiveness as disclosure requirements evolve across registries and regions.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement